Insulin treatment in children and adolescents

Acta Paediatrica, International Journal of Paediatrics

Volumn 93, Issue 4, 2004, Pages 440-446

  Williams, R M ^a   Dunger, D B ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Adolescents; Children; Diabetes; Glycaemic control; Insulin

Indexed keywords

GLUCOSE; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN;

ADOLESCENT; CHILD; DIABETES MELLITUS; EXERCISE; FEEDING BEHAVIOR; GLUCOSE BLOOD LEVEL; HORMONAL REGULATION; HUMAN; HYPOGLYCEMIA; INSULIN INFUSION; INSULIN TREATMENT; PRIORITY JOURNAL; PUBERTY; REVIEW; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPOGLYCEMIA; INSULIN; NUTRITIONAL REQUIREMENTS;

EID: 1842738318     PISSN: 08035253     EISSN: None     Source Type: Journal    
DOI: 10.1080/08035250410024934     Document Type: Review

References (50)

1. Oakley WG, Pyke DA, Tattersall RB, Watkins PJ. Long-term diabetes. A clinical study of 92 patients after 40 years. Q J Med 1974; 43: 145-56
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86
3. Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994; 125: 177-88
4. White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 2001; 139: 804-12
5. Rudberg S, Ullman E, Dahlquist G. Relationship between early metabolic control and the development of microalbuminuria - a longitudinal study in children with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 1309-14
6. Schultz CJ, Konopelska-Bahu T, Dalton RN, Carroll TA, Stratton I, Gale EA, et al. Microalbuminuria prevalence varies with age, sex, and puberty in children with type 1 diabetes followed from diagnosis in a longitudinal study. Oxford Regional Prospective Study Group. Diabetes Care 1999; 22: 495-502
7. Danne T, Mortensen HB, Hougaard P, Lynggaard H, Aanstoot HJ, Chiarelli F, et al. Persistent differences among centers over 3 years in glycemic control and hypoglycemia in a study of 3,805 children and adolescents with type 1 diabetes from the Hvidore Study Group. Diabetes Care 2001; 24: 1342-7
8. Holl RW, Swift PG, Mortensen HB, Lynggaard H, Hougaard P, Aanstoot HJ, et al. Insulin injection regimens and metabolic control in an international survey of adolescents with type 1 diabetes over 3 years: results from the Hvidore study group. Eur J Pediatr 2003; 162: 22-9
9. Marrero DG, Guare JC, Vandagriff JL, Fineberg NS. Fear of hypoglycemia in the parents of children and adolescents with diabetes: maladaptive or healthy response? Diabetes Educ 1997; 23: 281-6
10. Amiel SA, Simonson DC, Sherwin RS, Lauritano AA, Tamborlane WV. Exaggerated epinephrine responses to hypoglycemia in normal and insulin-dependent diabetic children. J Pediatr 1987; 110: 832-7
11. Matyka KA, Crowne EC, Havel PJ, Macdonald IA, Matthews D, Dunger DB. Counterregulation during spontaneous nocturnal hypoglycemia in prepubertal children with type 1 diabetes. Diabetes Care 1999; 22: 1144-50
12. Amin R, Ross K, Acerini CL, Edge JA, Warner J, Dunger DB. Hypoglycemia prevalence in prepubertal children with type 1 diabetes on standard insulin regimen: use of continuous glucose monitoring system. Diabetes Care 2003; 26: 662-7
13. Eckert B, Agardh CD. Hypoglycaemia leads to an increased QT interval in normal men. Clin Physiol 1998: 18: 570-5
14. Murphy NP, Ford-Adams ME, Keane SM, Ong KK, Davies K, Harris ND, et al. Prolonged QT interval during spontaneous nocturnal hypoglycaemia in children and adolescents with type 1 diabetes. Diabetes 2002; 51 Suppl 2: 8-OR, Page A2
15. Edge JA, Ford-Adams ME, Dunger DB. Causes of death in children with insulin dependent diabetes 1990-96. Arch Dis Child 1999; 81: 318-23
16. Tattersall RB, Gill GV. Unexplained deaths of type 1 diabetic patients. Diabet Med 1991; 8: 49-58
17. Sonnenberg GE, Kemmer FW, Berger M. Exercise in type 1 (insulin-dependent) diabetic patients treated with continuous subcutaneous insulin infusion. Prevention of exercise induced hypoglycaemia. Diabetologia 1990; 33: 696-703
18. Galassetti P, Mann S, Tate D, Neill RA, Costa F, Wasserman DH, et al. Effects of antecedent prolonged exercise on subsequent counterregulatory responses to hypoglycemia. Am J Physiol Endocrinol Metab 2001; 280: E908-17
19. Matyka KA, Wigg L, Pramming S, Stores G, Dunger DB. Cognitive function and mood after profound nocturnal hypoglycaemia in prepubertal children with conventional insulin treatment for diabetes. Arch Dis Child 1999; 81: 138-42
20. Rovet JF, Ehrlich RM. The effect of hypoglycemic seizures on cognitive function in children with diabetes: a 7-year prospective study. J Pediatr 1999; 134: 503-6
21. Northam EA, Anderson PJ, Jacobs R, Hughes M, Warne GL, Werther GA. Neuropsychological profiles of children with type 1 diabetes 6 years after disease onset. Diabetes Care 2001; 24: 1541-6
22. Caprio S, Cline G, Boulware S, Permanente C, Shulman GI, Sherwin RS, et al. Effects of puberty and diabetes on metabolism of insulin-sensitive fuels. Am J Physiol 1994;266 (6 Pt 1): E885-91
23. Edge JA, Dunger DB, Matthews DR, Gilbert JP, Smith CP. Increased overnight growth hormone concentrations in diabetic compared with normal adolescents. J Clin Endocrinol Metab 1990; 71: 1356-62
24. Edge JA, Matthews DR, Dunger DB. The dawn phenomenon is related to overnight growth hormone release in adolescent diabetics. Clin Endocrinol (Oxf) 1990; 33: 729-37
25. Edge JA, Matthews DR, Dunger DB. Failure of current insulin regimes to meet the overnight requirements of adolescents with insulin-dependent diabetes. Diabetes Res 1990; 15: 109-12
26. Del Sindaco P, Ciofetta M, Lalli C, Perriello G, Pampanelli S, Torlone E, et al. Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabet Med 1998; 15: 592-600
27. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-8
28. Dimitriadis GD, Gerich JE. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 1983; 6: 374-7
29. Mohn A, Matyka KA, Harris DA, Ross KM, Edge JA, Dunger DB. Lispro or regular insulin for multiple injection therapy in adolescence. Differences in free insulin and glucose levels overnight. Diabetes Care 1999; 22: 27-32
30. Howey DC, Bowsher RR, Brunelle RL, Rowe HM, Santa PF, Downing-Shelton J, et al. [Lys(B28), Pro(B29)]-human insulin: effect of injection time on postprandial glycemia. Clin Pharmacol Ther 1995; 58: 459-69
31. Heinemann L, Weyer C, Rave K, Stiefelhagen O, Rauhaus M, Heise T. Comparison of the time-action profiles of U40-and U100-regular human insulin and the rapid-acting insulin analogue B28 Asp. Exp Clin Endocrinol Diabetes 1997; 105: 140-4
32. ter Braak EW, Woodworth JR, Bianchi R, Cerimele B, Erkelens DW, Thijssen JH, et al. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care 1996; 19: 1437-40
33. Mortensen HB, Lindholm A, Olsen BS, Hylleberg B. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. Eur J Pediatr 2000; 159: 483-8
34. Rutledge KS, Chase HP, Klingensmith GJ, Walravens PA, Slover RH, Garg SK. Effectiveness of postprandial Humalog in toddlers with diabetes. Pediatrics 1997; 100: 968-72
35. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23: 644-9
36. Mohn A, Strang S, Wernicke-Panten K, Lang AM, Edge JA, Dunger DB. Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen. Diabetes Care 2000; 23: 557-9
37. Murphy NP, Keane SM, Ong KK, Ford-Adams M, Edge JA, Acerini CL, et al. Randomized cross-over trial of insulin glargine plus lispro or nph insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003; 26: 799-804
38. Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes. Diabetes Care 2001; 24: 2005-6
39. Dunger D, Edge J, Skvor J. Insulin glargine provides long-term effective glycaemic control in children and adolescents with type 1 diabetes. Diabetes 2002; 51 Suppl 2: A426
40. Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Larsen UD, Ribel U, et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 1995; 312 (Pt 3): 725-31
41. Kurtzhals P, Havelund S, Jonassen I, Markussen J. Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue. J Pharm Sci 1997; 86: 1365-8
42. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 2001; 24: 296-301
43. Vanelli M, Chiarelli F, Chiari G, Tumini S, Costi G, di Ricco L, et al. Metabolic control in children and adolescents with diabetes: experience of two Italian Regional Centers. J Pediatr Endocrinol Metab 1999; 12: 403-9
44. Bougneres PF, Landais P, Mairesse AM, Jais JP, Jos J, Peyraud J, et al. Improvement of diabetic control and acceptability of a three-injection insulin regimen in diabetic adolescents. A multicenter controlled study. Diabetes Care 1993; 16: 94-102
45. Ford-Adams ME, Murphy NP, Moore EJ, Edge JA, Ong KL, Watts AP, et al. Insulin lispro: a potential role in preventing nocturnal hypoglycaemia in young children with diabetes mellitus. Diabet Med 2003; 20: 656-60
46. Tamborlane WV, Sherwin RS, Genel M, Felig P. Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med 1979; 300: 573-8
47. Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999; 22: 1779-84
48. Boland E, Ahern J, Vincent M. Pumps and kids: basal requirements for excellent metabolic control. Diabetes 2002; 51 Suppl 2: 11-OR, Page A3
49. Kaufman FR, Gibson LC, Halvorson M, Carpenter S, Fisher LK, Pitukcheewanont P. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. Diabetes Care 2001; 24: 2030-4
50. Skyler JS, Cefalu WT, Kourides IA, Landschulz WH, Balagtas CC, Cheng SL, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 2001; 357: 331-5